Citations

Clear

941 citation(s) found for "Tefferi, A".

Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis
Anderson, Jeanne E., Tefferi, Ayalew , Craig, Fiona E. , Holmberg, Leona , Chauncey, Thomas R. , Appelbaum, Frederick R. , Guardiola, Philippe, Freytes, César O. , Gazitt, Yair, Razvillas, Betty, Deeg, H. Joachim , Holmberg, Leona , Callander, Natalie S.

Mayo Clinic

Blood | July 27, 2002 | Volume: 98 | Issue: 3 | Pages: 586-593

10.1182/blood.v98.3.586 | PMID 11468154 Get It

AbstractCurrent therapeutic options for myeloid metaplasia with myelofibrosis (MMM) are limited. A pilot study was conducted of autologous peripheral blood stem cell (PBSC) collection in 27, followed by transplantation in 21 patients with MMM. The median age was 59 (range 45-75) years. PBSCs were mobilized at steady state (n = 2), after granulocyte colony-stimulating factor (G-CSF) alone (n = 17), or after anthracycline-cytarabine induction plus G-CSF (n = 8). A median of 11.6 × 106 (range 0 to 410 × 106) CD34+ cells per kilogram were collected. Twenty-one patients then underwent myeloablation with oral busulfan (16 mg/kg) and PBSC transplantation. The median times to neutrophil and platelet recovery after transplantation were 21 (range 10-96) and 21 (range, 13 to ≥ 246) days, respectively. Five patients received back-up PBSC infusion because of delayed neutrophil or platelet recovery. The median follow-up is 390 (range 70-1623) days after transplantation, and the 2-year actuarial survival is 61%. After transplantion, 6 patients died: 3 of nonrelapse causes (1 within 100 days of PBSC infusion) and 3 of disease progression. Erythroid response (hemoglobin ≥ 100 g/L [10 gm/dL] without transfusion for ≥ 8 weeks) occurred in 10 of 17 anemic patients. Four of 8 patients with a platelet count less than 100 × 109/L (100 000/μL) responded with a durable platelet count more than 100 × 109/L (100 000/μL). Symptomatic splenomegaly improved in 7 of 10 patients. It is concluded that (1) PBSC collection was feasible and stable engraftment occurred after transplantation in most patients with MMM, (2) myeloablation with busulfan was associated with acceptable toxicity, (3) a significant proportion of patients derived clinical benefit after treatment, and (4) further investigation of this novel approach is warranted.
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma
Porrata, Luis F. , Inwards, David J. , Litzow, Mark R. , Lacy, Martha Q. , Tefferi, Ayalew , Gastineau, Dennis A., Dispenzieri, Angela , Ansell, Stephen M. , Micallef, Ivana N. , Geyer, Susan M. , Gertz, Morie A. , Markovic, Svetomir N. , Dispenzieri, Angela

Mayo Clinic

Blood | July 27, 2002 | Volume: 98 | Issue: 3 | Pages: 579-585

10.1182/blood.v98.3.579 | PMID 11468153 Get It

AbstractAutologous stem cell transplantation (ASCT) improves survival in patients with previously untreated multiple myeloma (MM) and relapsed, chemotherapy-sensitive, aggressive non-Hodgkin lymphoma (NHL). Lower relapse rates seen in allogeneic stem cell transplantation have been related to early absolute lymphocyte count (ALC) recovery as a manifestation of early graft-verus-tumor effect. In ASCT, the relation between ALC recovery and clinical outcomes in MM and NHL was not previously described. This is a retrospective study of patients with MM and NHL who underwent ASCT at the Mayo Clinic between 1987 and 1999. The ALC threshold was determined at 500 cells/μL on day 15 after ASCT. The study identified 126 patients with MM and 104 patients with NHL. The median overall survival (OS) and progression-free survival (PFS) times for patients with MM were significantly longer in patients with an ALC of 500 cells/μL or more than patients with an ALC of fewer than 500 cells/μL (33 vs 12 months,P < .0001; 16 vs 8 months, P < .0003, respectively). For patients with NHL, the median OS and PFS times were significantly longer in patients with an ALC of 500 cells/μL or more versus those with fewer than 500 cells/μL (not reached vs 6 months, P < .0001; not reached vs 4 months,P < .0001, respectively). Multivariate analysis demonstrated day 15 ALC to be an independent prognostic indicator for OS and PFS rates for both groups of patients. In conclusion, ALC is correlated with clinical outcome and requires further study.
Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes
Li, Chin‐Yang, Tefferi, Ayalew , Phyliky, Robert L., Go, Ronald S. , Li, Chin‐Yang

Mayo Clinic

Blood | July 27, 2002 | Volume: 98 | Issue: 2 | Pages: 483-485

10.1182/blood.v98.2.483 | PMID 11435321 Get It

Acquired pure red cell aplasia (PRCA) can be associated with lymphoproliferative disease of granular T lymphocytes (T-LDGL), also known as T-cell large granular lymphocyte leukemia. Fifteen adult patients with PRCA associated with T-LDGL comprise this study. Neutropenia and rheumatoid arthritis were uncommon. All patients responded to immunosuppressive therapy. The 2 most commonly used treatments were prednisone and cyclophosphamide ± corticosteroids, producing overall response rates of 50% and 60%, respectively. Treatment with cyclophosphamide was associated with a more durable remission (median, 60 versus 7.5 months). After a median follow-up of 67 months, 2 patients died of treatment-related complications, one from myelodysplasia and another from cyclosporine-induced renal failure. The clinical course and treatment responses of PRCA associated with T-LDGL in this series were similar to the general group of PRCA. Because T-LDGL is frequently underdiagnosed, it is likely that a significant proportion of idiopathic or primary PRCA is in fact secondary to T-LDGL.
Long-term use of anagrelide in young patients with essential thrombocythemia
Storen, Elizabeth C., Tefferi, Ayalew

Mayo Clinic

Blood | July 27, 2002 | Volume: 97 | Issue: 4 | Pages: 863-866

10.1182/blood.v97.4.863 | PMID 11159509 Get It

AbstractAnagrelide is a novel platelet-lowering agent that has recently been approved for use in essential thrombocythemia (ET) and related disorders. Short-term drug efficacy and toxicity data have previously been presented. The purpose of this study was to obtain additional information regarding long-term anagrelide use. This is a retrospective series of 35 young patients (17 to 48 years) with ET who received anagrelide treatment before 1992. Initial drug dosage ranged between 1 and 10 mg/d, and the median maintenance dosage was 2.5 mg/d. The overall initial response rate of 94% included 74% complete remissions and 20% partial remissions. Of the 33 responding patients, 27 (82%) remained on anagrelide therapy for a median of 10.8 years (range, 7 to 15.5). Of these, 66% maintained a complete and 34% a partial remission over the study period. In general, the reporting of somatic side effects decreased over time, and anemia was the only new side effect that emerged after long-term therapy. Eight patients (24%) experienced a more than 3 g/dL decrease in hemoglobin level. Despite active therapy, 20% of the patients experienced a total of 10 thrombotic episodes, and a similar proportion experienced major hemorrhagic events. All thrombohemorrhagic complications occurred at a platelet count of more than 400 × 109/L. It is concluded that long-term treatment of ET with anagrelide is associated with decreased reporting of initial side effects and the development of mild-to-moderate anemia. Complete normalization of platelet counts may be needed to minimize residual thrombohemorrhagic risk during therapy.
Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia
Li, Chin‐Yang, Schroeder, Georgene, Tefferi, Ayalew , Mesa, Ruben A. , Li, Chin‐Yang

Mayo Clinic

Blood | July 27, 2002 | Volume: 97 | Issue: 11 | Pages: 3665-3667

10.1182/blood.v97.11.3665 | PMID 11369668 Get It

Splenic extramedullary hematopoiesis is an integral component of myelofibrosis with myeloid metaplasia (MMM) and may be classified into 3 distinct histologic patterns of infiltration by myeloid precursors: diffuse, nodular, and a predominance of immature granulocytes. These 3 histologic patterns occurred in 121 (56.8%), 75 (35.2%), and 17 (8%), respectively, of 213 patients with MMM who underwent splenectomy at a single institution. In general, karyotypic findings in splenic tissue (n = 92) were similar to those seen in the bone marrow. The histologic pattern of immature granulocyte predominance, the presence of microscopic splenic infarcts (26 patients), or the detection of an abnormal splenic karyotype (52 patients) was significantly associated with decreased postsplenectomy survival. These adverse features were also associated with characteristics of advanced disease. These observations support the bone marrow origin of the myeloid progenitor pool in the spleen of patients with MMM and suggest a prognostic value for splenic histopathology and karyotype.
Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B
Morice, William G. , Kurtin, Paul J. , Tefferi, Ayalew , Hanson, Curtis A. , Morice, William George

Mayo Clinic

Blood | July 27, 2002 | Volume: 99 | Issue: 1 | Pages: 268-274

10.1182/blood.v99.1.268 | PMID 11756181 Get It

Unlike other leukemia types in which the bone marrow findings are diagnostic, the bone marrow pathology of T-cell granular lymphocytic leukemia (GLL) is subtle and ill-defined. In this study, bone marrow biopsy specimens from 36 patients with T-cell GLL and from 25 control patients with cytopenias and relative or absolute increases in blood large granular lymphocytes were studied by immunohistochemistry using antibodies to the cytolytic lymphocyte antigens CD8, CD56, CD57, TIA-1, and granzyme B. The goals were to clarify the bone marrow pathology of T-cell GLL and to refine the diagnostic criteria for T-cell GLL. Most bone marrow specimens from the T-cell GLL patients contained interstitially distributed clusters of at least 8 CD8+(83%) or TIA-1+ (75%) lymphocytes or clusters of at least 6 granzyme B+ (50%) lymphocytes. Interstitial clusters of CD8+, TIA-1+, or granzyme B+ cells were present in 36%, 12%, and 0%, respectively, of the control bone marrows (all values significantly different, P < .001). An additional T-cell GLL disease-specific finding was the presence of linear arrays of intravascular CD8+, TIA-1+, or granzyme B+ lymphocytes, found in 67% of cases of T-cell GLL and in none of the 25 control samples (P < .001). Staining for CD56 and CD57 was noncontributory. These findings clarify the bone marrow histopathology of T-cell GLL and provide an additional tool by which the discrete, abnormal lymphocyte population required for a diagnosis of T-cell GLL can be identified.
Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia
Tefferi, Ayalew , Elliott, Michelle A. , Li, Chin‐Yang, Call, Timothy G. , Yoon, Soo‐Young , Mesa, Ruben A. , Dispenzieri, Angela

Mayo Clinic

Blood | July 27, 2002 | Volume: 97 | Issue: 6 | Pages: 1896-1897

10.1182/blood.v97.6.1896 | PMID 11263440 Get It

Clarifications to the standard neutrophil response criteria for clinical trials in myelodysplastic syndromes are needed
Steensma, David P. , Letendre, Louis, Tefferi, Ayalew , Steensma, David P

Mayo Clinic

Blood | July 27, 2002 | Volume: 97 | Issue: 10 | Pages: 3321-3322

10.1182/blood.v97.10.3321 | PMID 11368066 Get It

Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro
Mow, Benjamin, Svingen, Phyllis A., Hallgren, Christopher G., Kottke, Timothy, Narayanan, V. L. , Litzow, Mark R. , Griffin, James D. , Sausville, Edward A., Tefferi, Ayalew , Chandra, Joya , Weisberg, Ellen , Kaufmann, Scott H.

Mayo Clinic

Blood | July 27, 2002 | Volume: 99 | Issue: 2 | Pages: 664-671

10.1182/blood.v99.2.664 | PMID 11781252 Get It

Abstract The adenosine triphosphate binding-site–directed agent STI571 and the tyrphostin adaphostin are undergoing evaluation as bcr/abl kinase inhibitors. The current study compared the effects of these agents on the survival of K562 cells, bcr/abl-transduced FDC-P1 cells, and myeloid progenitors from patients with chronic myelogenous leukemia (CML) compared with healthy donors. Treatment of K562 cells with 10 μM adaphostin resulted in decreased p210bcr/ablpolypeptide levels in the first 6 hours, followed by caspase activation and accumulation of apoptotic cells in less than 12 hours. By 24 hours, 90% of the cells were apoptotic and unable to form colonies. In contrast, 20 μM STI571 caused rapid inhibition of bcr/abl autophosphorylation without p210bcr/abl degradation. Although this was followed by the inhibition of Stat5 phosphorylation and the down-regulation of Bcl-xL and Mcl-1, only 7% ± 3% and 25% ± 9% of cells were apoptotic at 16 and 24 hours, respectively. Instead, the cytotoxic effects of STI571 became more pronounced with prolonged exposure, with IC90values greater than 20 μM and 1.0 ± 0.6 μM after 24 and 48 hours, respectively. Consistent with these results, 24-hour adaphostin exposure inhibited CML granulocyte colony-forming units (CFU-G) (median IC50, 12 μM) but not normal CFU-G (median IC50, greater than 20 μM), whereas 24-hour STI571 treatment had no effect on CML or normal CFU-G. Additional experiments revealed that STI571-resistant K562 cells remained sensitive to adaphostin. Moreover, the combination of STI571 + adaphostin induced more cytotoxicity in K562 cells and in CML CFU-G than either agent alone did. Collectively, these results identify adaphostin as a mechanistically distinct CML-selective agent that retains activity in STI571-resistant cell lines.
Bone Marrow Angiogenesis in Systemic Mast Cell Disease
Baek, Jin-Young, Li, Chin‐Yang, Pardanani, Animesh , Butterfield, Joseph H. , Tefferi, Ayalew , Li, Chin‐Yang

Mayo Clinic

Journal of Hematotherapy & Stem Cell Research | July 26, 2002 | Volume: 11 | Issue: 1 | Pages: 139-146

10.1089/152581602753448603 | PMID 11847010 Get It